Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2005
12/14/2005CN1231256C Non-aqueous proton peptide formulations
12/14/2005CN1231252C Medicine for treatnig ovarian cyst
12/14/2005CN1231239C Medicine for curing hydrocephalus, brain abscess and brain tumor and preparation process thereof
12/14/2005CN1231228C Drug moxibustion product with effect of promoting flow of qi and blood circulation and assuaging pain
12/14/2005CN1231221C Process for producing Liposome injection liquid of hydrochloric acid daunerubicin
12/14/2005CN1231220C New use of verbascum glycoside
12/14/2005CN1231209C Ursolic acid poly lactic acid nano particle freeze dried powder injection and its preparation method
12/13/2005US6974867 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
12/13/2005US6974836 Diamines as modulators of chemokine receptor activity
12/13/2005US6974830 For therapy of atherosclerosis, gallstone disease, lipid disorders, obesity or a cardiovascular disorder
12/13/2005US6974828 3-((2-((3-((Amino(imino)methyl)amino)benzoyl)amino)phenyl)sulf anyl)- 3-(3-pyridinyl)propanoic acid, for example; angiogenic inhibitors; antitumor, -carcinogenic, -metastatic, -diabetic, -arthritic and inflammatory agents; bone disorders
12/13/2005US6974826 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
12/13/2005US6974819 Alzheimer's disease; Parkinson's disease; Pick's disease; bipolar disorders; schizophrenia; alopecia; anticancer agents
12/13/2005US6974817 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP)
12/13/2005US6974813 For therapy of perioperative myocardial ischemic injury in mammals, including humans
12/13/2005US6974810 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
12/13/2005US6974809 Inhibitors of interleukin 1-β converting enzyme
12/13/2005US6974791 These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium.
12/13/2005US6974668 antitumor agent binds to base DNA or RNA sequence; measure cytolysis of tumor cells; drug screening
12/13/2005US6974594 Method of preparing biological materials and preparations produced using same
12/13/2005US6974589 Neutral-cationic lipid for nucleic acid and drug delivery
12/13/2005CA2280151C Arylsulfonyl hydroxamic acid derivatives
12/13/2005CA2271054C Substituted phenols and thiophenols useful as antioxidant agents
12/13/2005CA2234066C Substituted imidazoles having anti-cancer and cytokine inhibitory activity
12/10/2005CA2507847A1 Prostaglandin reductase
12/10/2005CA2507738A1 Modulation of peroxisome proliferator-activated receptors
12/08/2005WO2005116207A1 Telomerase-inhibitory ena oligonucleotide
12/08/2005WO2005116204A1 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
12/08/2005WO2005116067A2 Msh-agonist tripeptide conjugates
12/08/2005WO2005116066A1 Peptides derived from decorin leucine rich repeats and uses thereof
12/08/2005WO2005116056A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
12/08/2005WO2005116036A1 Curcumol derivatives, the compositions comprising the same and the use of the same in the manufacture of medicament
12/08/2005WO2005116019A1 Thioether derivatives, their manufacture and use as pharmaceutical agents
12/08/2005WO2005115476A1 Drug comprising as the active ingredient proliferative vector containing survivin promoter
12/08/2005WO2005115460A1 A method of producing polypeptides from plant protein and use of polypeptides
12/08/2005WO2005115450A1 Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
12/08/2005WO2005115408A1 Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation
12/08/2005WO2005115388A1 A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
12/08/2005WO2005115376A1 Pharmaceutical products for treating neoplastic disease and inflammation
12/08/2005WO2005115364A1 Antitumor agent
12/08/2005WO2005085196A3 Inhibitors of dna methylation in tumor cells
12/08/2005WO2005074968A3 Medical use of basic peptides
12/08/2005WO2005059172A3 Method and nucleic acids for the improved treatment of breast cell proliferative disorders
12/08/2005WO2005032452A3 Alkyl-substituted pcdf as a treatment for prostate cancer
12/08/2005WO2005009384A3 Egfr tyrosine kinase inhibitors
12/08/2005WO2005005627A3 Applications of a new class of enzymes: sulfiredoxines.
12/08/2005WO2003060148A3 Androgen regulated nucleic acid molecules and encoded proteins
12/08/2005WO2002066494A3 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
12/08/2005US20050272936 Imidazolium cxcr3 inhibitors
12/08/2005US20050272806 Injectable formulations of taxanes for cad treatment
12/08/2005US20050272798 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents
12/08/2005US20050272791 Lung melanoma metastasis, rheumatoid arthritis, 1-isopropylsulfonyl-2-amino-6-(2-(2,6-difluorophenyl)-5-(phenyl)-imidazol-4-yl)-benzimidazole
12/08/2005US20050272789 Triazole-derived kinase inhibitors and uses thereof
12/08/2005US20050272774 Substituted cyclohexane derivatives
12/08/2005US20050272761 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/08/2005US20050272760 Use of pyridoindolone derivatives for the preparation of medicinal products
12/08/2005US20050272751 Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine
12/08/2005US20050272733 1-substituted pyridine-2-ones or 2-substituted pyridazin-3-ones; anticarcinogenic agents for breast and prostate cancer; contraceptives; endometriosis, benign prostatic hypertophy
12/08/2005US20050272729 Cytotoxic agents comprising taxanes and their therapeutic use
12/08/2005US20050272709 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death
12/08/2005US20050272708 phosphoinositol ether lipid analogues and bioisosteres thereof;serine/threonine kinase (protein kinase B (PKB)) inhibitor; antitumor and anticarcinogenic agent; decreasing phosphorylation, increasing apoptosis in a tumor cell, and inhibiting pleckstrin homology (PH) domain binding
12/08/2005US20050272698 Liquid stable composition of oxazaphosphorine with mesna
12/08/2005US20050272685 Intraductal treatment targeting methylated promoters in breast cancer
12/08/2005US20050272684 Breast cancer resistance protein (BCRP) and the DNA which encodes it
12/08/2005US20050272683 Antisense oligonucleotides against thymidylate synthase
12/08/2005US20050272671 Compositions comprising hepoxilin analogs and their use in the treatment of cancer
12/08/2005US20050272658 Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (APP)
12/08/2005US20050272654 NF-kappaB activation inhibitors, and their pharmaceutical uses
12/08/2005US20050272633 Derivatives of the nf-kappab inducing enzyme, their preparation and use
12/08/2005US20050272151 Dendritic cell line
12/08/2005US20050272132 For therapy of a fungal infection
12/08/2005US20050272128 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
12/08/2005US20050272119 Polypeptides having 2',5'-oligoadenylate phosphodiesterase activity, antibodies against polypeptides, polynucleotides coding for polypeptides, recombinant plasmid DNAs into which polynucleotides have been inserted; for searching for antitumor agents, viricides
12/08/2005US20050272090 Nucleic acid binding of multi-zinc finger transcription factors
12/08/2005US20050271743 Treatment of inflammatory skin conditions
12/08/2005US20050271715 Conjugate having a cleavable linkage for use in a liposome
12/08/2005US20050271699 Biodegradable composition with prolonged release of the biological active compound and preparation thereof
12/08/2005US20050271673 Trifunctional reagent for conjugation to a biomolecule
12/08/2005US20050271669 For therapy of proliferative disease
12/08/2005US20050271652 Treatment of pathologies which escape the immune response, using optimised antibodies
12/08/2005US20050271620 Herpes simplex virus complex
12/08/2005US20050271588 Liposome targeting of matrix metalloproteinase inhibitors
12/08/2005DE19932216B4 Teilchen, insbesondere Mikroteilchen oder Nanoteilchen, aus vernetzten Monosacchariden und Oligosacchariden, Verfahren zu deren Herstellung und Verwendung der Teilchen als kosmetisches Mittel oder zur Herstellung pharmazeutischer Zusammensetzungen oder Nahrungsmittelzusammensetzungen Particles, in particular microparticles or nanoparticles of crosslinked monosaccharides and oligosaccharides, a process for their preparation and use of the particles as a cosmetic agent or for the preparation of pharmaceutical compositions or food compositions
12/08/2005CA2777821A1 Mhc molecule-binding tumor-associated peptides
12/08/2005CA2771941A1 Compositions and methods for bone formation and remodeling
12/08/2005CA2567959A1 Pharmaceutical products for treating neoplastic disease and inflammation
12/08/2005CA2567942A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
12/08/2005CA2566286A1 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
12/08/2005CA2566156A1 Method for treating abnormal cell growth
12/08/2005CA2565805A1 Msh-agonist tripeptide conjugates
12/08/2005CA2565263A1 2-styryl-4-oxazole-methanol-ethers and their use as tyrosine kinase inhibitors
12/08/2005CA2565257A1 Thioether derivatives, their manufacture and use as pharmaceutical agents
12/08/2005CA2563466A1 Anti-cytokine heterocyclic compounds
12/08/2005CA2562693A1 Reverse-turn mimetics and method relating thereto
12/07/2005EP1602669A1 Antibody against tumor specific antigen as target
12/07/2005EP1602659A1 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
12/07/2005EP1602647A1 Novel compound having 4-pyridylalkylthio group as substituent
12/07/2005EP1602380A1 Preventive/remedy for diseases in upper digestive tract
12/07/2005EP1602378A1 Method for administering a cytokine to the central nervous system and the lymphatic system
12/07/2005EP1602371A2 Valproic acid and derivatives for the sensitisation of human cancer cells to increase efficacy in a combination therapy
1 ... 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 ... 2211